Your session is about to expire
← Back to Search
Crisaborole for Eczema
Study Summary
This trial will test whether crisaborole can help kids with eczema by reducing their need for topical steroids.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not allergic to crisaborole, Aquaphor, or certain topical steroids.I am between 2 and 17 years old.My skin condition is severe, as rated by a doctor.I have been diagnosed with eczema.My Alzheimer's disease is mild to moderate.I am not pregnant or breastfeeding.I or my guardian(s) cannot follow the study's instructions.
- Group 1: Control
- Group 2: Vehicle
- Group 3: Crisaborole
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the age of eligibility for this trail restricted to adults above 25 years old?
"This research is accepting participants aged between 2 and 17 years."
Are there any remaining opportunities for patients to join this clinical trial?
"Affirmative. The information published on clinicaltrials.gov confirms that this trial is actively recruiting, having been posted on December 17th 2019 and recently updated on June 28th 2022. 60 subjects are required from a single medical site."
What are the criteria for enrolment in this experiment?
"A maximum of 60 minors between the ages 2-17 are able to participate in this study, provided they also meet other eligibility criteria. These include having a mild or moderate form of eczema as judged on the Investigator's Global Assessment scale (IGA) which ranges 0-4 with higher numbers indicating greater severity."
What potential risks do patients face when using Crisaborole?
"There is ample evidence supporting crisaborole's safety, resulting in this medication being allocated a score of 3."
How many participants are currently being recruited for this clinical trial?
"Yes, according to the information hosted on clinicaltrials.gov, this trial is actively recruiting patients and was first posted in December 2019 with a most recent update of June 2022. Around 60 participants are needed from one medical centre."
What ailments are regularly treated with Crisaborole?
"Crisaborole is the most common treatment for synovitis, but has been clinically proven to also treat ophthalmia, sympathetic disorders, skin inflammations and dermabrasion."
What prior experimentation has been done using Crisaborole?
"Presently, a total of 106 trials are underway exploring the potential benefits of Crisaborole. Of these investigations, 29 have advanced to Phase 3. While most studies for crisaborole originate in Boston ma, there are over 3000 locations globally conducting research into this treatment option."
What is the primary goal of this experiment?
"This clinical trial's chief objective is to measure the frequency of steroid usage over a 90-day period. Secondary goals comprise assessing severity of itching by Pruritus score (0 - 10, 0 meaning no itch and 10 representing unbearable irritation), Quality of Life for participants with Children's Dermatology Life Quality Index (0 - 30, higher numbers signifying greater impairment) and finally determining the impact on family members through Dermatitis Family Impact Questionnaire (0 -30; again, higher scores indicating more severe consequences)."
Share this study with friends
Copy Link
Messenger